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Abstract
Background: The misfolding of amyloidogenic proteins including human Tau protein, human prion protein, and human a-
synuclein is involved in neurodegenerative diseases such as Alzheimer disease, prion disease, and Parkinson disease.
Although a lot of research on such amyloidogenic proteins has been done, we do not know the determinants that drive
these proteins to form fibrils and thereby induce neurodegenerative diseases. In this study, we want to know the role of
fibril-forming motifs from such amyloidogenic proteins in the fibrillization of human Tau protein.
Methodology/Principal Findings: As evidenced by thioflavin T binding and turbidity assays, transmission electron
microscopy, and circular dichroism, fibril-forming motifs are essential and sufficient for the fibrillization of microtubule-
associated protein Tau: only when both of its fibril-forming motifs, PHF6 and PHF6*, are deleted can recombinant human
Tau fragment Tau244–372 lose its ability to form fibrils, and the insertion of unrelated fibril-forming motifs from other
amyloidogenic proteins, such as human prion protein, yeast prion protein, human a-synuclein, and human amyloid b, into
the disabled Tau protein can retrieve its ability to form fibrils. Furthermore, this retrieval is independent of the insertion
location on Tau244–372.
Conclusions/Significance: We demonstrate for the first time that insertion of fibril-forming motifs can replace PHF6/PHF6*
motifs, driving human Tau protein to form fibrils with different morphologies and different kinetic parameters. Our results
suggest that fibril-forming motifs play a key role in the fibrillization of human Tau protein and could be the determinants of
amyloidogenic proteins tending to misfold, thereby causing the initiation and development of neurodegenerative diseases.
Our study also touches on the importance of amyloid ‘‘strains’’: changes to the amyloidgenic driver region results in altered
structural morphologies at the macromolecular level.
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Introduction
The abnormal aggregation of proteins plays an important role
in the functions of proteins: the misfolding of amyloidogenic
proteins can cause serious neurodegenerative diseases, such as
human Tau protein and human amyloid b peptide in Alzheimer
disease, human a-synuclein in Parkinson disease, human polyglu-
tamine-containing peptides in Huntington disease, and human/
bovine prion proteins in prion diseases [1–7]; some are helpful for
organisms to survive in environmental threats, for example, Sup35
in yeast; and some are required for the normal functions of the
organisms [7], such as curlin in E. coli [7,8], Pmel17 in the
pigmentation of mammals [9], and many peptide or protein
hormones are stored in the form of amyloid fibrils [10].
Actually, the potential of misfolding of proteins are influenced
by many factors: abnormal cellular environments, including
aberrant ion concentrations [11,12] and unbalanced oxidative
stress [13]; covalent modification of proteins, such as the
hyperphosphorylation of Tau protein [13,14] and aged glycation
of b2-microglobulin [15,16]; crowded physiological environments
[14,17]; and pathogenic mutations in amyloidogenic proteins
which enable or promote their ability of aggregation [13,18].
However, according to Anfinsen’s dogma [19] the primary
structures of proteins may be the determinants of the potential
of aggregation of these proteins such as human Tau protein.
Human Tau can form fibrils without any posttranslational
modifications and any pathogenic mutations in vitro [12,20,21],
but mutation of the amino acid sequences does influence the
kinetics of Tau filament formation or even make the fibrillization
impossible [22,23].
Although a lot of research on such amyloidogenic proteins has
been done, we do not know the determinants that drive these
proteins to form fibrils and thereby induce neurodegenerative
diseases. Using methods such as NMR [24], proline-scanning [25],
and positive fibrillization assays [26,27], scientists have identified
some fibril-forming motifs from the reported amyloid proteins.
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crystals in vitro, and X-ray structures of these microcrystals reveal a
dry, tightly self-complementing steric zipper architecture model
[28,29]. Based on these data, researchers try to find determinants
of these proteins through bioinformatics methods [30–33]. A
algorithm based on these structures has been developed, and by
using this algorithm, the fibril-forming motifs are characterized as
peptides with their Rosetta energy below the threshold of -
23 kcal/mol [34,35]. A systematic genome-wide survey on
S. cerevisiae reveals that the enrichment of asparagines rather than
glutamines, and the spacing of prolines and charged amino acids
contribute to the aggregation of proteins [36].
Human microtubule-associated protein Tau is a natively
unfolded protein in solution [3,37]. Filamentous Tau has been
shown to be the main component of neurofibrillary tangles, a
pathological hallmark of Alzheimer disease [3,22,37–40]. Two
fibril-forming motifs
275VQIINK
280 (PHF6*) and
306VQIVYK
311
(PHF6) are very important for the fibrillization of Tau protein: the
fibrillization of a truncated fragment of Tau PHF43 requires the
existence of PHF6 [22]; mutations occurring in any of these fibril-
forming motifs will abrogate the ability of polymerization of the
truncated Tau protein [41]. Tau244–372, the core fragment of
human Tau protein, is a frequently used model for Tau
fibrillization, can form fibrils with the help of heparin in vitro in
a relatively short time [12,20,21].
In this study, we want to know the role of fibril-forming motifs
in the fibrillization of human Tau protein. We investigated the
potential primary structure determinants of filament formation of
human Tau protein by using several biophysical methods, such
as assays based on thioflavin T (ThT) binding and turbidity,
transmission electron microscopy (TEM), and far-UV circular
dichroism (CD). We demonstrated for the first time that insertion
of unrelated fibril-forming motifs from other amyloidogenic
proteins, such as human prion protein, yeast prion protein,
human a-synuclein, and human amyloid b, could replace PHF6/
PHF6* motifs of human Tau protein, driving Tau244–372 to form
fibrils with different morphologies and different kinetic param-
eters.
Materials and Methods
Ethics Statement
All research involving original human work was approved by
the Institutional Review Board of the College of Life Sciences,
Wuhan University (Wuhan, China), leaded by Dr. Hong-Bing
Shu, the Dean of the college, in accordance with the guidelines for
the protection of human subjects. Written informed consent for
the original human work that produced the plasmid samples was
obtained.
Materials
Heparin (average molecular mass of 6 kDa) and ThT were from
Sigma-Aldrich (St. Louis, MO). Dithiothreitol (DTT) was obtained
from Amresco (Solon, OH). DNA polymerase Kod-plus was from
Takara (Tokyo, Japan). Other chemicals used were made in China
and of analytical grade.
Plasmids and Proteins
The construction of plasmid expressing Tau244–372 was carried
as described [12]. The following primers for human Tau mutants
were synthesized, for example, P1, ACTGCCGCCTCCCGG-
GACGTGTTTGATATTATCC, P2, CAGCAGCAGCAGC
AGCAGCCAGTTGACCTGAGCAAGGTGACCTC-
CAAGTGTGG, P3, CTGCTG
CTGCTGCTGCTGACTGCCGCCTCCCGGGACGTGTTT-
GATATTATCC, and P4, CCAGTTGACCTGAGCAAGGT-
GACCTCCAAGTGTGG were designed to substitute VQIVYK
of Tau244–372 with QQQQQQ. 0.5 ml Kod-Plus (1 U/ml), 2.5 ml
106 Kod-Plus Buffer, 2.5 ml of 2 mM dNTP, 1 mlo f2 5m M
MgSO4,1 ml plasmid (about 50 ng/ml), 1 ml P1 (10 pmol/ml),
and 1 ml P2 (10 pmol/ml) were added into Tube A, and then
added Mini-Q water into adjust the total volume to 25 ml.
0.5 ml Kod-Plus (1 U/ml), 2.5 ml1 0 6 Kod-Plus Buffer, 2.5 mlo f
2 mM dNTP, 1 ml of 25 mM MgSO4,1 ml plasmid (about
50 ng/ml), 1 ml P3 (10 pmol/ml), and 1 ml P4 (10 pmol/ml) were
added into Tube B, and then added Mini-Q water into adjust
the total volume to 25 ml. The following PCR program was run
for tubes A and B: Step 1: 94uC for 2 min; Step 2: 94uC for
15 s; and Step 3: 68uC for 1 min/kb plasmid. Steps 2 and 3
were repeated for 25 times. Tubes A and B were mixed, and
the following program was run: Step 1: 98uC for 2 min; and
Step 2: 40uC for 1 min. Steps 1 and 2 were repeated for 3
times. The quantity of the product was checked with 1%
agarose gel and the product was digested with DpnI. Plasmids
containing target sequences were transformed into Escherichia coli
BL21 DE3 strain.
The expression of recombinant human Tau fragment Tau244–
372 and its mutants were induced with 400 mM isopropyl-b-D-
thiogalactopyranoside and cultured for 3 h. Cell pellets of 2 liter
culture were collected and re-suspended in 100 ml buffer A
(20 mM phosphate buffer containing 2 mM DTT, pH 7.0) and
then sonicated at 200 W for 30 min. 500 mM NaCl was added
into the mixture and then the mixture was boiled at 100uC for
15 min. After centrifugation at 17,000 g for 30 min at 4uC,
supernatant was collected and dialyzed against buffer A exten-
sively. The sample was then loaded onto a SP sepharose column
(20-ml bead volume) and washed with 400 ml buffer A. The target
protein was obtained by washing the column using 500 ml of
20 mM phosphate buffer containing 2 mM DTT and 0–400 mM
NaCl. Tau fragment was then concentrated and dialyzed against
50 mM Tris-HCl buffer containing 2 mM DTT (pH 7.5) exten-
sively, and then stored at 280uC. Purified Tau protein was
analyzed by SDS-PAGE with one band and confirmed by mass
spectrometry. The concentration of human Tau fragment was
determined according to its absorbance at 214 nm with a standard
calibration curve drawn by bovine serum albumin.
Fibrillization of Proteins
The fibrillization for Tau244–372 and its mutants was in a
mixture of 8 mM Tau protein, 2 mM heparin, and 1 mM DTT in
50 mM Tris-HCl buffer (pH 7.5) at 37uC for at least 10 h for ThT
binding assays and TEM experiments, or in a mixture of 20 mM
Tau protein, 20 mM heparin, and 1 mM DTT in 20 mM
NaH2PO4-Na2HPO4 buffer (pH 7.4) at 37uC for up to 24 h for
far-UV CD measurements, ThT binding assays, and TEM
experiments.
Thioflavin T Binding Assays
A 2.5 mM ThT stock solution freshly prepared in 50 mM Tris-
HCl buffer (pH 7.5) was added into the fibrillization system of Tau
protein, giving a final concentration of 16/40 mM. The kinetics
was monitored in 96-well plates at 37uC in SpectraMax M2
microplate reader (Molecular Devices, Sunnyvale, CA) using
excitation at 440 nm and emission at 480 nm with a wavelength
cut off at 475 nm, or in an LS-55 luminescence spectrometer
(PerkinElmer Life Sciences, Shelton, CT) using excitation at
440 nm and emission at 480 nm. Each sample was run in
triplicate.
Fibril-Forming Motifs for Tau Protein
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The fibrillization for Tau244–372 and its mutants was in a
mixture of 50 mM Tau protein, 12.5 mM heparin, and 1 mM
DTT in 50 mM Tris-HCl buffer (pH 7.5) at 37uC for up to 15 h
for turbidity assays. Turbidity at 350 nm was monitored in 96-well
plates at 37uC in SpectraMax M2 microplate reader (Molecular
Devices, Sunnyvale, CA). Each sample was run in triplicate.
Transmission Electron Microscopy
The formation of fibrils by Tau244–372 and its mutants was
confirmed by electron microscopy of negatively stained samples.
Sample aliquots of 10 ml were placed on carbon-coated copper
grids (Shanghai Mainstream Trading Company, Shanghai,
China), and left at room temperature for 1–2 min, rinsed with
H2O twice, and then stained with 2% (w/v) uranyl acetate for
another 1–2 min. The stained samples were examined using an
H-8100 transmission electron microscope (Hitachi, Tokyo, Japan)
operating at 100 kV or an FEI Tecnai G2 20 transmission
electron microscope (Hillsboro, OR) operating at 200 kV.
Far-UV CD Measurements
Under standard conditions, 20 mM Tau protein was incubated
in 20 mM NaH2PO4-Na2HPO4 buffer (pH 7.4) containing 1 mM
DTT and 20 mM heparin at 37uC for up to 24 h. Circular
dichroism spectra were obtained by using a Jasco J-810
spectropolarimeter (Jasco Corp., Tokyo, Japan) with a thermo-
stated cell holder. Quartz cell with a 1 mm light-path was used for
measurements in the far-UV region. Spectra were recorded from
195 to 250 nm for far-UV CD. The final concentration of Tau
protein for far-UV CD measurements was kept at 10 mM so that
the high tension voltage associated to CD spectra was less than
600 V. The spectra of all scans were corrected relative to the
buffer blank. The mean residue molar ellipticity [h] (deg? cm
2?
dmol
21) was calculated using the formula
½h ~(hobs=10)(MRW=lc), where hobs is the observed ellipticity
in deg, MRW the mean residue molecular weight (106.1 Daltons
for Tau fragment), l the path length in cm, and c the protein
concentration in g/ml.
Results
A Ligase-independent Plasmid Mutation Method
The sequences and source of unrelated fibril-forming motifs
inserted are listed in Table 1. Design of primers and protocol of
PCR are based on our new strategy, and the details are shown in
Fig. 1 and the corresponding figure legend. All of the mutants were
confirmed by DNA sequencing. Our sequencing results indicated
that this ligase-independent plasmid mutation method dramati-
cally increased the efficiency of short-fragment substitution by
transforming the classical blunt-end ligation into sticky end-
ligation, compared with the traditional QuickChange PCR
method.
Fibril-forming Motifs are Essential for the Fibrillization of
Tau244–372
It has been reported that PHF6 and PHF6* are both very
important for the fibrillization of human Tau protein but only
PHF6 is essential for filament formation [23]. Research on
PHF43, containing PHF6 but not PHF6* shows that, PHF6 is
essential for the fibrillization of that truncated peptides [22]. Three
mutants of Tau244–372, Tau244–372/DPHF6, Tau244–372/DPHF6*,
and Tau244–372/DPHF6/DPHF6* (Fig. 2A), were thus constructe-
d, expressed, and purified. We investigated fibril formation of
wild-type Tau244–372 and its three mutants by using ThT binding
assays, turbidity assays, TEM, and far-UV CD. During a relatively
long time of observation (100 h), Tau244–372/DPHF6/DPHF6*
Figure 1. Design of primers and protocol of PCR are based on
the following new strategy. This is a ligase-independent plasmid
mutation method. (A) Substitution of a relatively long fragment of DNA
in a plasmid with another one. To substitute the DNA fragment marked
with red color with another DNA fragment marked with black, two pair
of primers were designed. The first pair (2 and 3) were used to generate
linear double strand DNA molecular (dsDNA) with the target fragment
at the 39 end of the sensitive strand and the second pair (4 and 5) were
used to generate linear dsDNA with the target fragment at the 59 end of
the sensitive strand. (B) Primers for insertion of a DNA fragment to a
plasmid. To get an insertion of special DNA fragment indicated with
black color into a plasmid, the two pairs of primers (1–4) are designed
to amplify the whole plasmid to linear dsDNA with the target at the 59
or 39 end. (C) Some unique cases of mutagenesis. We also got some
unexpected results while try to constructs new mutagenesis. We
designed primers to insert six glutamines (Q) into the target location of
our gene, and besides the excepted products of 6Q-insertion, we also
get some 7Q-insertions. This, however, indicates that the products are
formed in the range of our plan. Based on this phenomenon, we
designed primers to generate PCR products that are not complemen-
tary completely with each other and we get the 8Q-insertion and 10Q-
insertion successfully.
doi:10.1371/journal.pone.0038903.g001
Table 1. Source of fibril-forming motifs in our experiments.
Fragment Source
SNQNNF Human prion protein [29]
NNQQNY Yeast prion Sup35 [28,29]
QQQQQQ Yeast prion SUP35 and human huntingtin
[29]
GVATVA Human a-synuclein [29,42]
GGVVIA Human amyloid b [29]
IFQINS Human lysozyme [29,34]
NHVTLS Human b2-microglobulin [27,29]
SQAIIH Myoglobin [29,34]
GGGGGG Negative control reported [42]
FERQHM Negative control from RNase A [35]
doi:10.1371/journal.pone.0038903.t001
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aggregation of wild-type Tau244–372 was the most rapid process
among these processes, and the kinetic curves reached the
maximum within about 1 h (Fig. 2C and 2D). The deletion of
one of the fibril-forming motifs influenced the kinetics of Tau
fibrillization markedly. As shown in Fig. 2C and 2D, the lag time
of either Tau244–372/DPHF6 or Tau244–372/DPHF6* was remark-
ably longer than that of Tau244–372, however, they finally proved
their ability of fibrillization. This is strong evidence showing that
both of the fibril-forming motifs are required for the fibrillization
of Tau244–372, and each of them can enable fibril formation of
Tau244–372. Because only when both of its fibril-forming motifs,
PHF6 and PHF6*, were deleted could recombinant human Tau
fragment Tau244–372 lose its ability to form fibrils, fibril-forming
motifs are essential for the fibrillization of human Tau protein.
To exclude the possibility that it is the deletion itself (the shorted
length of the protein) but not the fibril-forming motifs involved
contributes to the abrogation of fibrillization, we constructed
another mutation Tau244–372/DPHF6*/PHF6
306GSRSRT
through inserting a hexapeptide GSRSRT (Tau207–212), which
does not have the property of the fibril-forming motifs [42], into
Tau244–372/DPHF6* at the location of PHF6, as a negative
control. As shown in Fig. 3, such a mutant failed to aggregate on
the investigated time scale.
Our results suggest that the interaction of the two fibril-forming
motifs is not required for the fibrillization of Tau244–372 and that
both motifs perform their fibril-forming functions independently.
Insertion of Fibril-forming Motifs Replaces PHF6/PHF6*
Motifs, Driving Tau244–372 to Form Fibrils with Different
Morphologies and Different Kinetic Parameters
To determine whether other fibril-forming motifs can replace
PHF6/PHF6* motifs, we inserted fibril-forming motifs from other
amyloidogenic proteins, such as human prion protein, yeast prion
protein, human a-synuclein, and human amyloid b [27–29,34,42],
into the disabled Tau244–372/DPHF6/DPHF6*. Such fibril-form-
ing motifs are obtained from references indiscriminately, and the
detailed sequences and their sources are shown in Table 1. These
fibril-forming motifs can form fibrils or microcrystals in vitro, and
the crystal structures of some of them, such as SNQNNF and
NNQQNY, have been determined [27–29,34,42]. Figs. 4 and 5
representatively show negative-stain transmission electron micro-
graphs and kinetic curves for the aggregation of the following
mutants: insertion of SNQNNF, NNQQNY, QQQQQQ,
GVATVA, GGVVIA, IFQINS, NHVTLS, and SQAIIH, into
Tau244–372/DPHF6/DPHF6* at the location of PHF6. As
evidenced by ThT binding assays and TEM, although these
fibril-forming motifs come from different amyloidogenic proteins,
all of them did drive the disabled Tau protein to form fibrils under
moderate conditions (Figs. 4 and 5). As shown in Figs. 4 and 5,
although the fibril-forming motifs only make up of about 5% of the
amino acid sequences of these mutants, fibrils formed from such
different Tau mutants were of different morphologies and different
kinetic parameters. For example, insertion of GVATVA, a fibril-
forming motif from human a-synuclein [29,42], into Tau244–372/
DPHF6/DPHF6* at the location of PHF6 produced long and
branched fibrils (Fig. 4D) with shorter lag time and higher ThT
Figure 2. Fibril-forming motifs are essential for the fibrillization of Tau244–372. (A) Location of the two fibril-forming motifs
275VQIINK
280
(PHF6*) and
306VQIVYK
311 (PHF6) at Tau244–372: VQIINK is in the R2 part of Tau244–372, and VQIVYK is in the R3 part of Tau244–372. (B) Negative-stain
transmission electron micrographs of Tau244–372, Tau244–372/DPHF6, Tau244–372/DPHF6*, and Tau244–372/DPHF6/DPHF6* (scale bar 400 nm). (C) Kinetic
curves for the aggregation of Tau244–372, Tau244–372/DPHF6, Tau244–372/DPHF6*, and Tau244–372/DPHF6/DPHF6*, monitored by the turbidity at 350 nm.
The concentration of Tau protein was 50 mM, and 50 mM Tris-HCl buffer (pH 7.5) containing 1 mM DTT and 12.5 mM heparin was used. The assays
were carried out at 37uC. Tau244–372, Tau244–372/DPHF6, and Tau244–372/DPHF6* finished their progress of aggregation in a short time of observation
(15 h), but in a relatively long time of observation (100 h) Tau244–372/DPHF6/DPHF6* did not show any clue of aggregation (the inset of C). (D) Kinetic
curves for the aggregation of Tau244–372, Tau244–372/DPHF6, Tau244–372/DPHF6*, and Tau244–372/DPHF6/DPHF6*, monitored by ThT fluorescence. The
long time incubation of Tau244–372/DPHF6/DPHF6* is shown in the inset of D. The concentration of Tau protein was 8 mM, and 50 mM Tris-HCl buffer
(pH 7.5) containing 1 mM DTT and 2 mM heparin was used. The assays were carried out at 37uC. The observation time was 12 h for Tau244–372, Tau244–
372DPHF6, and Tau244–372DPHF6*, and 100 h for Tau244–372/DPHF6/DPHF6*.
doi:10.1371/journal.pone.0038903.g002
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forming motif from yeast prion SUP35 and human huntingtin
[30], into Tau244–372/DPHF6/DPHF6* produced short amyloid
fibrils (Fig. 4C) with much longer lag time and much lower ThT
fluorescence intensity (Fig. 5). Because the insertion of unrelated
fibril-forming motifs from other amyloidogenic proteins into the
disabled Tau protein could retrieve its ability to form fibrils, fibril-
forming motifs are sufficient for the fibrillization of human Tau
protein.
CD spectroscopy was used to further determine whether other
fibril-forming motifs can replace PHF6/PHF6* motifs. Fig. 6
shows the CD spectra of native Tau mutants and filaments
produced by Tau mutants. As shown in Fig. 6, at the beginning,
the CD spectra measured for all of Tau mutants had a strong
negative peak at 200 nm, indicative of a largely random coil
structure. After incubation for 24 h, a single minimum around
216 nm was observed for most of Tau mutant samples (Fig. 6A–
6C and 6E–6H), which is typical of predominant b-sheet structure
and a characteristic for filament formation. After incubation for
24 h, however, a single minimum around 211 nm (but not
216 nm) was observed for fibril sample of Tau244–372/DPHF6/
DPHF6* inserted by GVATVA (Fig. 6D), indicating that fibrils
formed by such a Tau mutant contained less b-sheet structure than
those formed by other Tau mutants.
We then inserted GGGGGG and FERQHM, two hexape-
tides predicted to have no ability to aggregate [35,42], into
Tau244–372/DPHF6/DPHF6* at the location of PHF6. As
revealed by TEM (Fig. 7) and CD spectroscopy (Fig. 8),
GGGGGG and FERQHM did not induce Tau filament
formation on the investigated time scale of 24 h. Our negative
control experiments verified that insertion of non-fibril forming
Figure 3. Tau244–372/DPHF6*/PHF6
306GSRSRT does not aggre-
gate on the investigated time scale. (A) Kinetic curves for the
aggregation of Tau244–372/DPHF6*/PHF6
306GSRSRT, monitored by ThT
fluorescence. The concentration of Tau protein was 8 mM, and 50 mM
Tris-HCl buffer (pH 7.5) containing 1 mM DTT and 2 mM heparin was
used. The assays were carried out at 37uC, and the observation time was
12 h. (B) Kinetic curves for the aggregation of Tau244–372/DPHF6*/
PHF6
306GSRSRT, monitored by the turbidity at 350 nm. The concentra-
tion of Tau protein was 50 mM, and 50 mM Tris-HCl buffer (pH 7.5)
containing 1 mM DTT and 12.5 mM heparin was used. The assays were
carried out at 37uC, and the observation time was 15 h.
doi:10.1371/journal.pone.0038903.g003
Figure 4. Insertion of fibril-forming motifs from other amyloi-
dogenic proteins into the disabled Tau protein can retrieve its
ability to form fibrils2TEM measurements. Negative-stain trans-
mission electron micrographs of the following mutants: insertion of
SNQNNF (A), NNQQNY (B), QQQQQQ (C), GVATVA (D), GGVVIA (E),
IFQINS (F), NHVTLS (G), and SQAIIH (H) into Tau244–372/DPHF6/DPHF6*
at the location of PHF6 after incubation for 24 h. All the scale bars were
200 nm.
doi:10.1371/journal.pone.0038903.g004
Figure 5. Insertion of fibril-forming motifs from other amyloi-
dogenic proteins into the disabled Tau protein can retrieve its
ability to form fibrils2ThT binding assays. Kinetic curves for the
aggregation of Tau244–372/DPHF6/DPHF6* inserted by SNQNNF (black),
NNQQNY (red), QQQQQQ (green), GVATVA (blue), GGVVIA (magenta),
IFQINS (wine), NHVTLS (navy), and SQAIIH (pink), monitored by ThT
fluorescence. The concentration of Tau protein was 20 mM, and 20 mM
NaH2PO4-Na2HPO4 buffer (pH 7.4) containing 1 mM DTT and 20 mM
heparin was used. The assays were carried out at 37uC, and the
observation time was 10 h.
doi:10.1371/journal.pone.0038903.g005
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amyloid fibrils (Figs. 3, 7, and 8).
Clearly, insertion of fibril-forming motifs from other amyloi-
dogenic proteins, such as human prion protein, yeast prion
protein, human a-synuclein, and human amyloid b, could
replace PHF6/PHF6* motifs of human Tau protein, driving
Tau244–372 to form fibrils with different morphologies and
different kinetic parameters.
The Retrieval is Independent of the Insertion Location on
Tau244–372
It has been reported that fibril-forming motifs can drive a non-
fibrillizing protein RNase A to the amyloid state, and the insertion
is located at C-terminal hinge loop, although it is long known that
RNase A is capable of forming domain-swapped oligomers [42].
The insertion location may supply the possibility for fibril-forming
motifs to exposed to the outside of the protein and thereby the
interaction between fibril-forming motifs happens, which is
important for protein aggregation [34]. To determine whether
this retrieval depends on the insertion location, we inserted one of
the fibril-forming motifs, IFQINS, into Tau244–372/DPHF6/
DPHF6* at four different locations and obtained four mutants,
W31, W56, W78, and W98 (Fig. 9A). These locations were chosen
randomly. The results from ThT binding and turbidity assays and
TEM showed that all four mutants had the ability to form fibrils
(Fig. 9B–9D and Fig. 4), indicating that the retrieval of
fibrillization function is independent of the insertion location of
fibril-forming motifs on Tau244–372.
Impact of the Length of the Fibril-forming Motifs on
Tau244–372 Fibrillization Kinetics
Mutants generated from the insertion of a different fibril-
forming motif into Tau244–372/DPHF6/DPHF6* had different
kinetic parameters (Fig. 5). We obtained kinetic parameters for
Tau mutants by fitting the experimental data to the empirical Hill
equation [14,21]:
F(t)~F(?)
(t=t50)
n
1z(t=t50)
n ð1Þ
Here F(‘) is the fluorescence intensity in the long time limit, t50 is
the elapsed time at which F is equal to one-half of F(‘), and n is a
cooperativity parameter.
The length of polyQ has been demonstrated to be involved in
fibrillization kinetics of intracellular huntingtin aggregate forma-
tion [43,44]. We thus constructed a series of mutants inserted by
different number of glutamines into Tau244–372/DPHF6/
DPHF6*. Data from ThT binding assays of these mutants were
fitted to Eq. 1 and three kinetic parameters were obtained and
compared. As shown in Table 2, the number of glutamines
inserted into Tau244–372/DPHF6/DPHF6* had different effects
on fibrillization kinetic parameters for these Tau mutants. F(‘)
increased remarkably with the number of glutamines inserted
and then decreased to some extent with the number of
glutamines larger than 7, and n increased noticeably with the
Figure 6. Insertion of fibril-forming motifs from other amyloidogenic proteins into the disabled Tau protein can retrieve its ability
to form fibrils2CD measurements. Far-UV CD spectra of the following mutants: insertion of SNQNNF (A), NNQQNY (B), QQQQQQ (C), GVATVA
(D), GGVVIA (E), IFQINS (F), NHVTLS (G), and SQAIIH (H) into Tau244–372/DPHF6/DPHF6* at the location of PHF6. Curve a: native Tau protein. Curve b:
filaments produced from Tau protein after incubation for 24 h. The CD signals have no signs of high tension voltage saturation and all of the curves
here have been smoothed.
doi:10.1371/journal.pone.0038903.g006
Figure 7. GGGGGG and FERQHM did not induce Tau filament
formation2TEM measurements. Negative-stain transmission elec-
tron micrographs of the following mutants: insertion of GGGGGG (B)
and FERQHM (C), two hexapetides predicted to have no ability to
aggregate, into Tau244–372/DPHF6/DPHF6* (A) at the location of PHF6
after incubation for 24 h. All the scale bars were 200 nm.
doi:10.1371/journal.pone.0038903.g007
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number of glutamines. Our data demonstrated that the length of
the fibril-forming motifs is involved in fibrillization kinetics of
Tau mutants.
Discussion
In the present study, we perform all fibrillization experiments in
the presence of the inducer heparin, not only for wild-type Tau244–
372 and deletion mutants, but also for insertion variants. It is
known that poly-anions such as heparin trigger fibrillization of
human Tau protein [12,20–23,41]. Therefore it would be
interesting to explore whether these insertion mutants no longer
require heparin for aggregation, since these sequences themselves
are generally able to assemble in the absence of heparin [29]. Our
additional experiments verified that only one of the eight insertion
mutants can form fibrils in the absence of heparin but the others
can not form fibrils in the absence of heparin on the investigated
time scale of 14 days (Figs. S1 and S2). As shown in Figs. S1 and
S2F, insertion of IFQINS, a fibril-forming motif from human
lysozyme [29,34], into Tau244–372/DPHF6/DPHF6* at the
location of PHF6 produced straight filaments in the absence of
heparin (Fig. S2F) with much longer lag time and remarkable
lower ThT fluorescence intensity (Fig. S1), compared with those in
the presence of heparin (Fig. 5). It has been reported that the
binding of heparin to Tau monomer induces conformational
changes in Tau, as well as reducing the large net positive charge
borne by Tau protein, thus reducing the activation energy
required to add Tau to the end of a growing Tau fiber and
accelerating fibril growth [20]. Therefore, it is possible that the
Tau sequence outside PHF6/PHF6* motifs relies on presence of
heparin for assembly and that it is due to fibril-forming motifs to
balance negative effects of the ‘non’-amyloidogenic regions. The
fibril-forming ability of IFQINS is so strong that such an insertion
mutant no longer requires heparin for aggregation.
The absorbance traces of all the forms in Fig. 2 converge to a
signal of about 0.2. The same happens in ThT traces. A possible
explanation for this behavior has been proposed. Fibrils formed by
wild-type Tau244–372 and its two single deletion mutants are
probably loose and of more b-sheet structure during the middle
time period. At the final stage, however, the fibrils will become
more compact and some b-sheet structure will be buried, leading
to reduced turbidity and reduced accessibility of ThT-binding
sites.
It should be pointed out that different fibrillization conditions
were used in this work. As shown in Figs. 2 and S3 (8 mM Tau
protein, 2 mM heparin, and Tris-HCl buffer) and Figs. 4, 5, 6, 7, 8
(20 mM Tau protein, 20 mM heparin, and phosphate buffer), the
change of fibrillization conditions does not affect the phenomena
we are observing that fibril-forming motifs are essential and
sufficient for the fibrillization of human Tau, although such
conditions are usually associated to changes in the aggregation rate
of human Tau [20] and possibly morphology.
Fibril-forming motifs found from amyloidogenic proteins have
been reported to be important for the misfolding of these proteins:
theycanformfibrilsinvitro,andthedamageoftheirabilitytoformb-
sheet via site-directed substitution with proline will disturb or even
erase the misfolding of these proteins composing them [34,42]. The
present study demonstrated that insertion of fibril-forming motifs
from other amyloidogenic proteins, such as human prion protein
and human a-synuclein, could replace PHF6/PHF6* motifs of
human Tauprotein, driving Tau244–372 toform fibrils, butinsertion
of non-fibril forming peptides could not replace PHF6/PHF6*
motifs, unable to drive Tau244–372 to form fibrils. Furthermore,
fibrilsproducedbysuchTaumutantswereofdifferentmorphologies
and different kinetic parameters, although the fibril-forming motifs
only make up of about 5% of the amino acid sequences of these
mutants. The data all supports the view that PHF6 and 6* regions
are important for aggregation and that deletion of both regions
Figure 8. GGGGGG and FERQHM did not induce Tau filament
formation2CD measurements. Far-UV CD spectra of the following
mutants: insertion of GGGGGG (B) and FERQHM (C) into Tau244–372/
DPHF6/DPHF6* (A) at the location of PHF6. Curve a: native Tau protein.
Curve b: Tau protein after incubation with heparin and DTT at 37uC for
24 h. The CD signals have no signs of high tension voltage saturation
and all of the curves here have been smoothed.
doi:10.1371/journal.pone.0038903.g008
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other amyloidogenic proteins rescues assembly ability in the double
deletion mutant, although results in altered morphologies. Our
study impacts on the importance of sequence for amyloidogenesis
andalsotouchesontheimportanceofamyloid‘‘strains’’:changesto
the amyloidgenic driver region results in altered structural
morphologies at the macromolecular level. Because these changes
in morphology may reflect the structures of the short peptides alone
[29]anddifferentfibrilmorphologiesmayhavedifferentunderlying
molecular structures [45,46], it would be worthwhile to extend the
current work to investigate whether each ‘‘driver’’ peptide can
propagate a particular morphology. These are planned for the
future. Our results here suggest that fibril-forming motifs play a key
role in the fibrillization of human Tau protein and could be the
determinants of amyloidogenic proteins tending to misfold, thereby
causing the initiation and development of neurodegenerative
diseases. Thus it is a possible to slow down, stop, or even clear the
misfolding of amyloidogenic proteins via blocking their fibril-
forming motifs by drugs. In fact, fibril-forming motif LVEALYL
from insulin has been successfully used to block the fibrillization of
insulin [47]. Such a fibril-forming motif can form complementary
stericzipperstructurewithLVEALYLininsulin,andthusshieldthe
space and suppress the fibrillization of insulin [47]. Using known
atomicstructuresoffibril-formingmotifsastemplates,theEisenberg
lab has recently designed and characterized an all-D-amino-acid
inhibitor of the fibrillization of Tau protein [48], and has presented
atomic structures of fibril-forming motifs of proteins involved in
Alzheimer disease incomplex withsmall molecule binders [49]. We
also tried to block the fibrillization of human Tau with one of its
fibril-formingmotifsVQIVYK,butunfortunatelyfailedtoblockthe
fibrillization ofhumanTau. This,however,suggeststhat,weshould
Figure 9. The retrieval is independent of the location of the insertion on Tau244–372. (A) Four insertions of IFQINS into different locations.
W31, W56, W78, and W98 represent Tau mutants in which IFQINS was inserted between 30th and 31th, 55th and 56th, 77th and 78th, and 97th and
98th amino acids of Tau244–372 respectively. W56 is the same as the mutant inserted by IFQINS at the location of PHF6, and its negative-stain
transmission electron micrograph is shown in Figure 4. (B) Kinetic curves for the aggregation of W31, W78, and W98, monitored by ThT fluorescence.
The concentration of Tau protein was 8 mM, and 50 mM Tris-HCl buffer (pH 7.5) containing 1 mM DTT and 2 mM heparin was used. The assays were
carried out at 37uC, and the observation time was 12 h. (C) Kinetic curves for the aggregation of W31, W78, and W98, monitored by the turbidity at
350 nm. The concentration of Tau protein was 50 mM, and 50 mM Tris-HCl buffer (pH 7.5) containing 1 mM DTT and 12.5 mM heparin was used. The
assays were carried out at 37uC. (D) Negative-stain transmission electron micrographs of W31, W78, and W98 (scale bar 400 nm) after incubation for
12 h.
doi:10.1371/journal.pone.0038903.g009
Table 2. Kinetic parameters for the growth of ThT
fluorescence intensity of mutants inserted by different
number of glutamines into Tau244–372/DPHF6/DPHF6*.
F(‘) t50 (min) n
6Q 102.463.6 5.960.3 2.560.2
7Q 183.565.6 5.860.2 5.260.6
8Q 69.465.4 7.660.4 5.761.5
10Q 81.964.3 5.660.3 8.763.7
Best-fit values of these kinetic parameters were derived from non-linear least
squares modeling of the Hill equation to the experimental data. The
concentration of Tau protein was 20 mM, and 20 mM NaH2PO4-Na2HPO4 buffer
(pH 7.4) containing 1 mM DTT and 20 mM heparin was used. The assays were
carried out at 37uC, and the observation time was 24 h. The 6 sign is a standard
deviation.
doi:10.1371/journal.pone.0038903.t002
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own fibril-forming motifs in the future.
Although amyloid fibrils can cause many serious diseases of
human being, they are very interesting and useful state of proteins.
Amyloids are very stable, as they are acid resistant, alkali resistant,
and protease resistant, and can exist for a relative long time [7–
10]. Amyloids can drive macromolecules into a super high local
concentrations and such an enrichment will have a dramatic
effect, and it has been reported that amyloid formed by Sup35p
can increase the sensitivity of immunoassay up to 100-fold with
protein G and methyl-parathion hydrolase attached with it [50].
Our results make it possible that fibril-forming motifs could be
fused into proteins including enzymes, antibodies, and structural
proteins and change their structural stability, sensitivity, capacity
to resist extreme environments, and other functions at nanometer
level. In this study we find that fibril-forming motifs are of different
capacity to drive fibril formation: some of them, for example
IFQINS from human lysozyme [29,34], if inserted in the proper
locations, they will form beautiful fibrils with higher intensity of
ThT fluorescence and lower turbidity (Figs. 4F, 5, and 9B–9D). In
the next step, we will try to fuse fibril-forming motifs to some
proteins and test the change of their functions.
In conclusion we focus on the role of fibril-forming motifs in the
fibrillizationofhumanTau,andhaveshownthat:(i)deletionofboth
PHF and PHF6* hexapeptide motifs eliminates fibrillization
propensity of human Tau; (ii) insertion of unrelated fibril-forming
motifs from other amyloidogenic proteins, such as human prion
proteinandhumana-synuclein,canreplacePHF6/PHF6*motifsof
human Tau, driving Tau244–372 to form fibrils with different
morphologies and different kinetic parameters; (iii) insertion of
non-fibrilformingpeptidescannotreplacePHF6/PHF6*motifs;(iv)
theretrievaloffibrillizationfunctiondoesnotdependontheinsertion
location of fibril-forming motifs on human Tau; (v) fibril-forming
motifsareessentialandsufficientforthefibrillizationofhumanTau.
Information obtained from the present study can enhance our
understanding of the molecular mechanisms of neurodegenerative
diseasessuchasAlzheimerdiseaseandpriondisease,andshouldlead
to a better understanding of how proteins misfold and how proteins
avoid misfoldinginphysiological environments.
Supporting Information
Figure S1 One of the eight insertion mutants can form
fibrils in the absence of heparin but the others can
not2ThT binding assays. Kinetic curves for the aggregation
of Tau244–372/DPHF6/DPHF6* inserted by SNQNNF (black),
NNQQNY (red), QQQQQQ (green), GVATVA (blue),
GGVVIA (magenta), IFQINS (wine), NHVTLS (navy), and
SQAIIH (pink) incubated in the absence of heparin, monitored
by ThT fluorescence. The concentration of Tau protein was
20 mM, and 20 mM NaH2PO4-Na2HPO4 buffer (pH 7.4) con-
taining 1 mM DTT was used. The assays were carried out at
37uC, and the observation time was 14 days.
(DOC)
Figure S2 One of the eight insertion mutants can form
fibrils in the absence of heparin but the others can
not2TEM measurements. Negative-stain transmission elec-
tron micrographs of the following eight mutants: insertion of
SNQNNF (A), NNQQNY (B), QQQQQQ (C), GVATVA (D),
GGVVIA (E), IFQINS (F), NHVTLS (G), and SQAIIH (H) into
Tau244–372/DPHF6/DPHF6* at the location of PHF6 after
incubation for 14 days in the absence of heparin. Amyloid fibrils
were clearly observed (F). All the scale bars were 200 nm.
(DOC)
Figure S3 Insertion of fibril-forming motifs from other
amyloidogenic proteins into the disabled Tau protein
can retrieve its ability to form fibrils2ThT binding
assays. Kinetic curves for the aggregation of Tau244–372/
DPHF6/DPHF6* inserted by SNQNNF (black), NNQQNY
(red), QQQQQQ (green), GVATVA (blue), GGVVIA (magenta),
IFQINS (wine), NHVTLS (navy), and SQAIIH (pink), monitored
by ThT fluorescence. The concentration of Tau protein was
8 mM, and 50 mM Tris-HCl buffer (pH 7.5) containing 1 mM
DTT and 2 mM heparin was used. The assays were carried out at
37uC, and the observation time was 10 h.
(DOC)
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